aspirin and Activated Protein C Resistance
aspirin has been researched along with Activated Protein C Resistance in 14 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Activated Protein C Resistance: A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial." | 2.73 | Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007) |
| "Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition." | 2.42 | [Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003) |
| "Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%." | 1.37 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011) |
| "Protein C and protein S deficiency were found in nine and two patients, respectively." | 1.32 | Venous thrombosis among patients with AIDS. ( Corona-de la Peña, N; de Chávez-Ochoa, AR; Majluf-Cruz, A; Montiel-Manzano, G; Nieto-Cisneros, L; Sánchez-Barboza, R; Santoscoy-Gómez, M; Silva-Estrada, M; Treviño-Pérez, S, 2004) |
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Sabouni, R | 1 |
| Gorra Al Nafouri, M | 1 |
| Hanafi, I | 1 |
| Al Droubi, I | 1 |
| Alhalabi, M | 1 |
| Ozçakar, L | 1 |
| Dönmez, G | 1 |
| Yörübulut, M | 1 |
| Aydog, ST | 1 |
| Demirel, H | 1 |
| Pasaoglu, I | 1 |
| Doral, MN | 1 |
| Zamagni, E | 1 |
| Brioli, A | 1 |
| Tacchetti, P | 1 |
| Zannetti, B | 1 |
| Pantani, L | 1 |
| Cavo, M | 1 |
| Tchan, M | 1 |
| Sillence, D | 1 |
| Kahn, JE | 1 |
| Veyssier-Belot, C | 1 |
| Renier, JL | 1 |
| de Mazancourt, P | 1 |
| Peltier, JY | 1 |
| de Raucourt, E | 1 |
| Hickstein, H | 1 |
| Barz, D | 1 |
| Külz, T | 1 |
| Korten, G | 1 |
| Müller, H | 1 |
| Schmidt, R | 1 |
| Abraitis, V | 1 |
| Mongirdiene, A | 1 |
| Mockeviciene, A | 1 |
| Granel, B | 1 |
| Serratrice, J | 1 |
| Ene, N | 1 |
| Morange, PE | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Majluf-Cruz, A | 1 |
| Silva-Estrada, M | 1 |
| Sánchez-Barboza, R | 1 |
| Montiel-Manzano, G | 1 |
| Treviño-Pérez, S | 1 |
| Santoscoy-Gómez, M | 1 |
| de Chávez-Ochoa, AR | 1 |
| Corona-de la Peña, N | 1 |
| Nieto-Cisneros, L | 1 |
| Lewerenz, V | 1 |
| Burchardt, T | 1 |
| Büchau, A | 1 |
| Ruzicka, T | 1 |
| Megahed, M | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Glynn, RJ | 1 |
| Ridker, PM | 1 |
| Goldhaber, SZ | 1 |
| Zee, RY | 1 |
| Buring, JE | 1 |
| Brenner, B | 1 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Younis, JS | 1 |
| Schütt, M | 1 |
| Klüter, H | 1 |
| Wiedemann, GJ | 1 |
| Richardt, G | 1 |
Reviews
2 reviews available for aspirin and Activated Protein C Resistance
| Article | Year |
|---|---|
[Factor V Leiden mutation and pregnancy complications].
Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem | 2003 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
Trials
1 trial available for aspirin and Activated Protein C Resistance
| Article | Year |
|---|---|
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Aspirin; Double-Blind Method; Drug A | 2007 |
Other Studies
11 other studies available for aspirin and Activated Protein C Resistance
| Article | Year |
|---|---|
Activated protein C resistance impact on Syrian candidates for in vitro fertilisation and the benefit of anticoagulation therapy: a retrospective cohort study.
Topics: Activated Protein C Resistance; Anticoagulants; Aspirin; Canada; Female; Fertilization in Vitro; Hep | 2022 |
Paget-Schroetter syndrome forerunning the diagnoses of thoracic outlet syndrome and thrombophilia.
Topics: Activated Protein C Resistance; Anticoagulants; Aspirin; Enoxaparin; Factor V; Heterozygote; Humans; | 2010 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib | 2011 |
Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; beta-Thalas | 2002 |
Protein A immunoadsorption in a pregnant woman with habitual abortion.
Topics: Abortion, Habitual; Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; An | 2002 |
Juvenile temporal arteritis and activated protein C resistance.
Topics: Activated Protein C Resistance; Adult; Anti-Inflammatory Agents; Aspirin; Giant Cell Arteritis; Huma | 2004 |
Venous thrombosis among patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Activated Protein C Resistance; Adult; Aspirin; HIV Protease Inh | 2004 |
[Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome].
Topics: Activated Protein C Resistance; Anticoagulants; Aspirin; Blood Platelets; Factor V; Fibrinolytic Age | 2004 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulatio | 2000 |